Patents by Inventor Yanming Zu
Yanming Zu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11801233Abstract: The present disclosure relates to an oral eliglustat transmucosal delivery system. More specifically, the present disclosure is related to an oral transmucosal dosage form comprising a non-disintegrating solid mass comprising (a) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (b) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons and (c) not more than 70 mg eliglustat, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec share rate. The dosage forms of as described herein have at least 30% dose reduction as compared to commercially available eliglustat capsules.Type: GrantFiled: July 6, 2022Date of Patent: October 31, 2023Assignee: ABON PHARMACEUTICALS, LLCInventors: Salah U. Ahmed, Yanming Zu, Tahseen A. Chowdhury, Saad Muntazim, Mohammed Irfan Syed
-
Publication number: 20230248720Abstract: The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C6-C24 fatty acid, or (b) a hydrophilic organic compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and dimethylsulfoxide, or (c) a combination of (a) and (b), and (iii) an amphiphilic agent wherein the active pharmaceutical ingredient is dispersed as discrete panicles having a D90 particle size of about 0.5 ?m to about 25 ?m in the formulation, and wherein the formulation is non-gelling and thixotropic with a viscosity of less than 10 poise at a shear rate of 10/s at 25° C.Type: ApplicationFiled: May 2, 2023Publication date: August 10, 2023Inventors: Salah U. AHMED, Yanming ZU, Jason LePREE, Hetalben PRAJAPATI, Tahseen A. CHOWDHURY
-
Patent number: 11596628Abstract: The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C6-C24 fatty acid, or (b) a hydrophilic organic compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and dimethylsulfoxide, or (c) a combination of (a) and (b), and (iii) an amphiphilic agent wherein the active pharmaceutical ingredient is dispersed as discrete particles having a D90 particle size of about 0.5 ?m to about 25 ?m in the formulation, and wherein the formulation is non-gelling and thixotropic with a viscosity of less than 10 poise at a shear rate of 10/s at 25° C.Type: GrantFiled: October 24, 2016Date of Patent: March 7, 2023Assignee: Abon Pharmaceuticals, LLCInventors: Salah U. Ahmed, Yanming Zu, Jason LePree, Hetalben Prajapati, Tahseen A. Chowdhury
-
Publication number: 20230000824Abstract: The present disclosure relates to an oral eliglustat transmucosal delivery system. More specifically, the present disclosure is related to an oral transmucosal dosage form comprising a non-disintegrating solid mass comprising (a) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (b) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons and (c) not more than 70 mg eliglustat, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec share rate. The dosage forms of as described herein have at least 30% dose reduction as compared to commercially available eliglustat capsules.Type: ApplicationFiled: July 6, 2022Publication date: January 5, 2023Inventors: Salah U. AHMED, Yanming ZU, Tahseen A. CHOWDHURY, Saad MUNTAZIM, Mohammed Irfan SYED
-
Patent number: 11413271Abstract: The present disclosure relates to an oral eliglustat transmucosal delivery system. More specifically, the present disclosure is related to an oral transmucosal dosage form comprising a non-disintegrating solid mass comprising (a) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (b) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons and (c) not more than 70 mg eliglustat, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec share rate. The dosage forms of as described herein have at least 30% dose reduction as compared to commercially available eliglustat capsules.Type: GrantFiled: June 7, 2019Date of Patent: August 16, 2022Assignee: ABON PHARMACEUTICALS LLCInventors: Salah U. Ahmed, Yanming Zu, Tahseen A. Chowdhury, Saad Muntazim, Mohammed Irfan Syed
-
Publication number: 20210379090Abstract: The present disclosure provides a remdesivir oral delivery system bypassing the first pass hepatic metabolism. More specifically, the disclosure relates to an oral dosage form of remdesivir comprising a lipid based vehicle in an enteric capsule designed to be delivered at intestine to be absorbed by lymphatic pathway, therefore minimizing the first pass hepatic metabolism and improving the oral bioavailability. In some embodiments, the disclosure provides an oral dosage form comprising: (a) remdesivir; (b) a lipid-based vehicle comprising a lipophilic vehicle, an amphiphilic vehicle, a none-aqueous hydrophilic vehicle, or combinations thereof; and (c) an enteric capsule; wherein the remdesivir is dissolved or dispersed in the lipid-based vehicle; and, wherein the remdesivir and the lipid-based vehicle are in the enteric capsule. It also relates to methods of designing and making this dosage form, and methods of usage of this dosage form in the early treatment and prophylaxis of coronavirus infections, e.g.Type: ApplicationFiled: June 7, 2021Publication date: December 9, 2021Inventors: Salah U. AHMED, Yanming ZU, Hetalben PRAJAPATI, Mohammed I. SYED, Tahseen A. CHOWDHURY
-
Patent number: 10821118Abstract: This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms.Type: GrantFiled: September 25, 2017Date of Patent: November 3, 2020Assignee: Abon Pharmaceuticals LLCInventors: Salah U. Ahmed, Yanming Zu, Karunakar Neelam, Saad Muntazim, Tahseen A. Chowdhury, Shiying Tian
-
Publication number: 20190388392Abstract: The present disclosure relates to an oral eliglustat transmucosal delivery system. More specifically, the present disclosure is related to an oral transmucosal dosage form comprising a non-disintegrating solid mass comprising (a) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (b) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons and (c) not more than 70 mg eliglustat, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec share rate. The dosage forms of as described herein have at least 30% dose reduction as compared to commercially available eliglustat capsules.Type: ApplicationFiled: June 7, 2019Publication date: December 26, 2019Inventors: Salah U. AHMED, Yanming ZU, Tahseen A. CHOWDHURY, Saad MUNTAZIM, Mohammed Irfan SYED
-
Publication number: 20180015102Abstract: This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms.Type: ApplicationFiled: September 25, 2017Publication date: January 18, 2018Applicant: ABON PHARMACEUTICALS, LLCInventors: Salah U. AHMED, Yanming ZU, Karunakar NEELAM, Saad MUNTAZIM, Tahseen A. CHOWDHURY, Shiying TIAN
-
Patent number: 9795616Abstract: This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms.Type: GrantFiled: April 29, 2016Date of Patent: October 24, 2017Assignee: Abon Pharmaceuticals LLCInventors: Salah U. Ahmed, Yanming Zu, Karunakar Neelam, Saad Muntazim, Tahseen A. Chowdhury, Shiying Tian
-
Publication number: 20170196802Abstract: The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C6-C24 fatty acid, or (b) a hydrophilic organic compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and dimethylsulfoxide, or (c) a combination of (a) and (b), and (iii) an amphiphilic agent wherein the active pharmaceutical ingredient is dispersed as discrete particles having a D90 particle size of about 0.5 ?m to about 25 ?m in the formulation, and wherein the formulation is non-gelling and thixotropic with a viscosity of less than 10 poise at a shear rate of 10/s at 25° C.Type: ApplicationFiled: August 12, 2016Publication date: July 13, 2017Applicant: Abon Pharmaceuticals, LLCInventors: Salah U. AHMED, Yanming ZU, Jason LePREE, Hetalben PRAJAPATI, Tahseen A. CHOWDHURY
-
Publication number: 20170196855Abstract: The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C6-C24 fatty acid, or (b) a hydrophilic organic compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and dimethylsulfoxide, or (c) a combination of (a) and (b), and (iii) an amphiphilic agent wherein the active pharmaceutical ingredient is dispersed as discrete particles having a D90 particle size of about 0.5 ?m to about 25 ?m in the formulation, and wherein the formulation is non-gelling and thixotropic with a viscosity of less than 10 poise at a shear rate of 10/s at 25° C.Type: ApplicationFiled: October 24, 2016Publication date: July 13, 2017Applicant: Abon Pharmaceuticals, LLCInventors: Salah U. AHMED, Yanming ZU, Jason LePREE, Hetalben PRAJAPATI, Tahseen A. CHOWDHURY
-
Publication number: 20160235764Abstract: This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms.Type: ApplicationFiled: April 29, 2016Publication date: August 18, 2016Applicant: ABON PHARMACEUTICALS, LLCInventors: Salah U. AHMED, Yanming ZU, Karunakar NEELAM, Saad MUNTAZIM, Tahseen A. CHOWDHURY, Shiying TIAN
-
Patent number: 9352047Abstract: This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms.Type: GrantFiled: November 14, 2013Date of Patent: May 31, 2016Assignee: ABON PHARMACEUTICALS, LLCInventors: Salah U. Ahmed, Yanming Zu, Karunakar Neelam, Saad Muntazim, Tahseen A. Chowdhury, Shiying Tian
-
Patent number: 9011912Abstract: Oral dosage forms for poorly soluble amine drugs are provided. Such dosage forms include an ionizable compound such as an organic acid, an amphiphilic polymer and a release rate-controlling membrane. Such dosage forms allow for the consistent release of the active agent in both gastric pH conditions and in the intestine. Methods of making such dosage forms are also provided.Type: GrantFiled: October 7, 2010Date of Patent: April 21, 2015Assignee: Abon Pharmaceuticals, LLCInventors: Yanming Zu, Sudhir Gorukanti, Salah Uddin Ahmed
-
Publication number: 20140142076Abstract: This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms.Type: ApplicationFiled: November 14, 2013Publication date: May 22, 2014Applicant: ABON PHARMACEUTICALS, LLCInventors: Salah U. AHMED, Yanming ZU, Karunakar NEELAM, Saad MUNTAZIM, Tahseen A. CHOWDHURY, Shiying TIAN
-
Publication number: 20120087979Abstract: Oral dosage forms for poorly soluble amine drugs are provided. Such dosage forms include an ionizable compound such as an organic acid, an amphiphilic polymer and a release rate-controlling membrane. Such dosage forms allow for the consistent release of the active agent in both gastric pH conditions and in the intestine. Methods of making such dosage forms are also provided.Type: ApplicationFiled: October 7, 2010Publication date: April 12, 2012Applicant: ABON PHARMACEUTICALS, LLCInventors: Yanming Zu, Sudhir Gorukanti, Salah Uddin Ahmed
-
Publication number: 20110287096Abstract: Oral dosage forms for basic amine drugs, the dosage forms having a gastro-retentive component and a non gastro-retentive component. These dosage forms are capable of providing both IR and SR release rates for these drugs. In addition, they provide for release of the drug in the stomach and/or intestine of a mammal to which such dosage forms are administered. Such dosage forms include tablets and capsules. Such dosage forms provide improved bioavailability of otherwise poorly bioavailable basic amine drugs.Type: ApplicationFiled: May 18, 2011Publication date: November 24, 2011Applicant: ABON PHARMACEUTICALS, LLCInventors: Sudhir GORUKANTI, Yanming Zu, Phanidhara Kotamraj, Karunakar Neelam, Salah U. Ahmed
-
Publication number: 20090196935Abstract: The present invention is directed to pharmaceutical capsules comprising extended release formulations of dipyridamole, processes for preparing such dipyridamole extended release formulations and their use in the treatment of stroke.Type: ApplicationFiled: February 2, 2009Publication date: August 6, 2009Inventors: Salah U. Ahmed, Pruthvipathy R. Katikaneni, Yanming Zu